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Abstract
Background—Phase III trials have revealed benefit of radiation therapy (ART) for men with 
adverse factors at radical prostatectomy, however, some patients have high progression risk despite 
ART. The role of systemic therapy with ART in this high-risk group remains to be defined.
Methods—Patients post-RP with PSA nadir > 0.2 and Gleason ≥ 7 or PSA nadir ≤ 0.2, Gleason ≥ 
8 and ≥ pT3 received six months ADT + RT and six cycles of docetaxel. The primary objective 
was to assess whether addition of ADT/docetaxel to ART results in freedom from progression 
(FFP) ≥70% Vs. an expected rate of 50%. Multivariate logistic and Cox regression were used to 
model association of factors with outcomes.
Results—74 patients were enrolled. Median follow-up was 4.4 years. T classification: pT2 (4%), 
pT3 (95%) and pT4 (1%); Gleason 7 (18%) and ≥8 (82%); Post-RP PSA: ≤0.2 (53%) and >0.2 
47%. Three year FFP was 73% (95% CI:61%–83%). Three year cumulative incidence of 
biochemical, distant, and local failure were 26%, 7%, and 0%. In multivariate models, post-
prostatectomy PSA nadir was associated with three year FFP; Gleason score and PSA with 
biochemical failure. Grade 3–4 neutropenia was common however only three cases of febrile 
neutropenia occurred. Late toxicities were not impacted by addition of systemic therapy.
Conclusions—Combination of ADT, docetaxel, and ART for men with high-risk prostate cancer 
post-prostatectomy exceeded the pre-specified study endpoint of 70% three-year FFP. Phase III 
trials assessing combined local and systemic therapies for these high-risk patients are warranted.
Keywords
post-prostatectomy; radiation; androgen deprivation; chemotherapy; docetaxel; high risk
Introduction
Radical prostatectomy (RP) is common treatment for prostate cancer. Although a majority of 
patients with favorable risk features do well, those with high-risk features have a substantial 
risk of disease recurrence. Patients with persistently elevated PSA post-prostatectomy or 
who experience biochemical failure within three years of surgery have a significantly 
increased risk of death from prostate cancer.1
Radiation therapy is commonly used post-prostatectomy. Randomized trials of adjuvant 
radiation therapy (ART) showed improvement in progression-free survival, and with long-
term follow-up an overall survival advantage.2–4 Despite this overall benefit, 50% of patients 
with pathologic T3 and Gleason ≥ 8 disease or Gleason ≥ 7 and PSA nadir > 0.2 ng/ml 
experienced treatment failure within three years. This subset of patients are failing despite 
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both surgery and radiation therapy and therefore are expected to be at greater risk of death 
from prostate cancer than those who fail only surgery.
Optimal therapies for high risk patients despite radiotherapy in the post-prostatectomy 
setting remain to be defined. Standard care for high-risk patients receiving primary 
radiotherapy includes androgen deprivation therapy (ADT).5 Docetaxel has been shown to 
improve survival in men with metastatic prostate cancer6–8 and recently a potential survival 
benefit has been noted in treatment of high-risk clinically localized disease.9 The present 
study was designed to test the hypothesis that addition of docetaxel and ADT to radiation in 
men at high risk of failure despite ART would result in improved freedom from progression 
as compared with historical controls.
Methods
Patient Eligibility
Protocol approval was received from the Institutional Review Board at each site. Informed 
consent was obtained from patients prior to participation. Eligible patients had prostatic 
adenocarcinoma with either Gleason ≥ 7 at prostatectomy and PSA nadir > 0.2 ng/ml or 
Gleason ≥ 8 at prostatectomy, PSA nadir ≤ 0.2 ng/ml, and T classification ≥ pT3a. Patients 
were enrolled within one year of RP. Subjects had no lymph node or distant metastases 
determined by bone scan and magnetic resonance imaging or computer tomography of the 
pelvis.
A Zubrod performance status of ≤1 was required. PSA was obtained ≤ 6 weeks before 
registration. Absolute neutrophil count ≥ 2,000 cells/mm3, platelet count ≥ 100,000 
cells/mm3, hemoglobin ≥ 8.0 g/dl, ALT or AST ≤ 1.5 times, alkaline phosphatase ≤ 2.5 
times and total bilirubin ≤ 1.2 times the institutional upper normal limit were required.
Treatment
ADT including an LHRH agonist and non-steroidal anti-androgen (bicalutamide 50mg 
daily) were administered for six months beginning eight weeks prior to RT.
RT was administered with either 3D-conformal radiation therapy (3DCRT) or intensity 
modulated radiation therapy (IMRT) using energies ≥ 6 MV. Total dose to the prostate bed 
was 6660 cGy (+/−180 cGy) including an initial pelvic field of 4500 cGy using daily 
fractions of 180 cGy. Pelvic fields included a superior border extending at a minimum to the 
bottom of the sacroiliac joint and at most superiorly to the L5-S1 interspace. Seminal vesicle 
remnants if present received a minimum of 5040 cGy and could receive full dose at the 
discretion of the treating physician.
Docetaxel was administered 3–6 weeks after completion of radiation therapy. Patients 
received six cycles of 75mg/m2 intravenously every three weeks. Pre-medication with 
dexamethasone was required. If granulocytes were ≤ 1,500 cell/mm3 or platelets ≤100,000 
as measured within a day of docetaxel administration, treatment was held and counts 
repeated weekly with modification of subsequent docetaxel doses. If neutropenia/
thrombocytopenia did not resolve to a point that allowed docetaxel administration by 15 
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days of scheduled chemotherapy, chemotherapy was discontinued. Docetaxel was also 
modified or held due to abnormal liver function tests. Dose was reduced by 25% for Grade 2 
neuropathy without treatment delay or discontinued for Grade ≥ 3 neuropathy.
Follow-Up
Follow-up assessments occurred every three months for two years, every six months for 
three more years, then annually. PSA was obtained at each visit. PSA of ≥ 0.4 ng/ml was 
verified with a repeat level to confirm progression. Bone scans and CT or MRI were 
recommended at least annually after PSA progression to determine rates of metastatic 
progression.
Statistical Design and Analysis
The primary endpoint was freedom from progression (FFP), where failure was defined as 
PSA ≥ 0.4 ng/mL after end of RT confirmed by second higher PSA, non-protocol hormones, 
local-regional progression, distant metastasis, or death, within three years after registration. 
Per SWOG 8794, the expected FFP rate was 50% for patients treated with prostatectomy 
and RT. The experimental therapy was to be deemed effective if FFP rate was ≥ 70%. Per 
Fleming’s multiple testing procedure with three stages, 69 patients were required to test the 
null hypothesis (FFP ≤ 50%) against the alternative (FFP ≥ 70%) with 90% power and 
significance level 0.025. Allowing for 10% patient ineligibility or non-evaluability, total 
sample size was 76. At final analysis, if ≥ 44 of 69 had no FFP event, (i.e., were alive and 
progression-free), the null hypothesis would be rejected and we would conclude FFP rate is 
≥ 0.7. The 95% confidence interval for FFP rate was calculated using the Clopper-Pearson 
method.
Secondary endpoints included FFP (at any time), local-regional progression, distant 
metastases, biochemical failure, overall survival, prostate cancer death, non-prostate-cancer 
death, and acute [within 90 days of treatment end (three weeks after last planned docetaxel 
dose)] and late (≥ 91 days after treatment end) treatment-related (definitely, probably, or 
possibly related to treatment) adverse events. Adverse events were scored using Common 
Terminology Criteria for Adverse Events (CTCAE) version 3.0. FFP and survival rates were 
estimated by Kaplan-Meier method and all others by cumulative incidence method, with 
death prior to failure as competing risk. Age, Gleason score, PSA, TN stage, and surgical 
margins were correlated with outcomes by logistic or Cox regression.
Results
Eighty patients from 33 sites were enrolled between April, 2008 and September, 2010 of 
which 74 meeting eligibility requirements were included in analysis. Details of patient 
enrollment are shown in Figure 1. Patient characteristics are shown in Table 1. Post-RP PSA 
was ≤ 0.2 in 39 patients (52.7%) and >0.2 ng/ml in 35 (47.3%). Among patients with post-
RP PSA > 0.2, the median was 0.60 (IQR 0.40 to 2.49). Surgical margins were positive in 43 
patients (58.1%).
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Freedom from progression in the first three years
Since final analysis is out of 74 patients, ≥ 46 patients with no FFP event (i.e., were alive 
and progression-free) were required to reject the null hypothesis (rather than 44). Fifty-four 
of 74 had no FFP event so the null hypothesis was rejected. Estimated FFP rate is 73.0% 
(95%CI 61.4–82.6). Post-RP PSA > 0.2 was associated with increased risk of failure in 
univariate [odds ratio 10.94 (95%CI 2.68–65.81), p<0.001] and multivariate analysis [odds 
ratio 16.27 (95%CI 3.51–108.17), p<0.001)] adjusted for Gleason score (8–10 vs. 7).
Time-to-event outcomes
Median follow-up among surviving patients was 4.4 years (range 3.3–5.6). Three-year FFP 
was 73.0% (95%CI 62.9–83.1) (Figure 2). Twenty-six patients experienced treatment failure 
including 20 within three years. Biochemical failure was the first event noted in 24 (92.3%) 
with 2 (7.7%) presenting with metastases as the initial sign of treatment failure. Eleven 
subjects developed metastases. Three deaths including two from prostate cancer occurred. 
Three-year estimates are presented in Table 2. Gleason score 8–10 and post-RP PSA > 0.2 
were associated with increased risk of failure for endpoints FFP and biochemical failure in 
multivariate analysis, but only PSA > 0.2 showed increased risk in univariate analysis (Table 
3). Discrepant results for Gleason score between univariate and bivariate analysis are likely 
due to the eligibility criteria, where patients with Gleason 7 were only eligible with PSA > 
0.2. In univariate analysis, post-RP PSA > 0.2 is also associated with increased risk of 
distant metastasis [hazard ratio 12.62 (95%CI 1.61–98.65), p=0.02)].
Treatment delivery
Sixty-six of 74 patients (89.2%) were scored by study chairs as per protocol or with 
acceptable variation for radiation therapy. Seventy of 74 (94.6%) were scored per protocol 
for chemotherapy, with 61 of 70 having no modifications or delays. 89.2% received IMRT, 
9.5% 3DCRT, and one no RT. All 73 patients that started RT received 66.6Gy +/− 1.8. Sixty-
seven of 74 patients (90.5%) received six cycles of docetaxel; one patient did not receive any 
docetaxel. All patients received LHRH agonist and all but one received oral antiandrogen.
Adverse events
Chemotherapy side effects were common but manageable and did not increase long-term 
toxicity. Thirty-five patients (47.3%) experienced at least one Grade 4 and an additional 23 
(31.1%) at least one Grade 3 treatment-related adverse event at any time. Acute treatment-
related adverse events are summarized in Table 4. The most common acute toxicities were 
hematologic including Grade 3 and 4 neutropenia (16.2 and 40.5%), leukopenia (35.1 and 
13.5%) and lymphopenia (13.5 and 2.7%). However, only 4.1% of patients developed febrile 
neutropenia and infection was limited to a single case of a Grade 3 urinary tract infection. 
Grade 2 and 3 peripheral neuropathy occurred in 13.5% and 1.4% respectively. Late 
treatment related toxicities included six (8.1%) various Grade 3 and two (2.7%) cases of 
Grade 4 urinary incontinence (Table 5). Two-year cumulative incidence of Grade 3–4 late 
toxicity was 8.1% (95%CI 3.3–15.8).
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Discussion
Phase III trials studies have consistently demonstrated a benefit to the use of adjuvant 
radiation therapy for men with adverse pathologic findings following prostatectomy 
including extracapsular disease extension, seminal vesicle invasion, or positive margins.2–4 
All three randomized studies showed benefit in progression-free survival and in SWOG 
8794 with long-term follow-up an overall survival benefit was noted.
While adjuvant radiation post-prostatectomy will benefit many men, review of studies 
assessing post-prostatectomy radiation reveal subsets of patients at high risk of failure 
following both surgery and radiation. In a large series from Johns Hopkins, men who 
experienced treatment failure within three years of prostatectomy had a 15 year risk of 
prostate cancer specific mortality of 59% compared to 13% who experienced treatment 
failure at a longer period post-operatively. In design of the current study, a subgroup of 
patients from the SWOG 8794 study were identified with on average a 50% risk of failure by 
three years despite addition of adjuvant radiation. Given these patients are at high risk of 
failing two local therapies, the current study was designed to assess the potential benefit of 
adding docetaxel and ADT to radiation in this high-risk population.
While the roles of ADT and chemotherapy in combination with postoperative radiotherapy 
have yet to be defined, survival benefit has been noted with ADT and potential benefit with 
docetaxel in other high-risk settings. Addition of ADT to primary use of radiotherapy is 
standard in the setting of high-risk prostate cancer with established survival benefit. Phase 
III trials have also revealed survival benefit with docetaxel in metastatic prostate cancer, 
initially in the setting of castration resistant disease6,7 and more recently a large survival 
benefit was noted in the CHAARTED study when administered with initiation of ADT for 
newly diagnosed metastatic castration sensitive disease.8 The STAMPEDE trial showed 
benefit in metastatic disease and potential utility in the locally advanced setting and initial 
results of RTOG 0521 indicate there may be a survival benefit in primary treatment of high-
risk patients.9,10 Benefit seen with use of docetaxel at earlier points in the course of prostate 
cancer supports investigation of its use in high-risk patients post-prostatectomy without 
frank evidence of metastases but likely to fail despite local therapy. The findings of the 
currently study support the hypothesis that use of systemic therapy benefits men without 
established metastatic disease but who are at high risk of local treatment failure despite both 
radical prostatectomy and post-operative RT. Three year freedom from progression was 73% 
compared to a projected rate of 50% observed among patients with high-risk features on the 
adjuvant radiation arm of SWOG 8794. While comparison between studies must be viewed 
with caution, on review of patient characteristics and known prognostic factors, subjects 
enrolled on the current study appear to be a higher risk cohort compared to the SWOG 
historical controls. 82% of subjects on the current study had Gleason 8–10 disease vs. 9% in 
the historical control series. PSA failed to nadir to ≤ 0.2 in 47% of subjects on the current 
study vs. 36% from SWOG 8794. 57% of subjects on the current study had seminal vesicle 
involvement vs. 31% from SWOG 8794 and fewer had positive margins. All these factors 
have been associated with greater risk of treatment failure in prior studies including SWOG 
8794.11 Furthermore, both PSA nadir and Gleason score were associated with increased risk 
of treatment failure on multivariate analysis on the current study suggesting that the benefit 
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to addition of systemic therapy in these very high-risk patients may exceed the estimated 
23%.
Additional study of docetaxel in high-risk patients post-prostatectomy is indicated noting 
both the potential benefits and toxicities. High rates of hematologic toxicities including 
Grade 3 and 4 neutropenia and leukopenia occurred on the current study. These rates appear 
higher than previously reported series assessing use of docetaxel in treatment of metastatic 
prostate cancer likely reflecting initiation of docetaxel three to six weeks after the 
completion of pelvic radiation.7,11–13 The impact of timing of initiation of docetaxel 
following radiation on hematologic toxicities warrants further investigation. While 
concurrent use of docetaxel with radiation may have sensitizing effects as commonly 
employed in treatment of other malignancies, the rates of hematologic toxicity noted on the 
present study support the sequential use of pelvic radiation and docetaxel in this clinical 
setting. It is important to note that while rates of these laboratory toxicities were high, rates 
of febrile neutropenia and infection were similar to previously reported series.7,12 Rates of 
other toxicities commonly associated with docetaxel including peripheral neuropathy were 
in line with expected rates.13 Notably use of docetaxel and ADT in the current study was not 
associated with increased long term toxicities including exacerbation of genitourinary and 
gastrointestinal side effects common with radiation therapy.4,14
It is important to note limitations of the current study. Due to the non-randomized phase II 
design, the impact of each intervention including radiation, ADT, and docetaxel on 
improvement in freedom from progression compared to historical controls remains to be 
defined. Improved surgical techniques and changes in Gleason grading since completion of 
SWOG 8794 might have accounted for some of the benefit seen on NRG Oncology RTOG 
0621. However, this concern is significantly mitigated by the comparatively higher risk 
factors of subjects enrolled on NRG Oncology RTOG 0621 including more subjects with 
persistently detectable PSA post-operatively. It is unlikely that change in Gleason grading 
over time, can account for the large discrepancy in numbers of high risk (Gleason ≥ 8) 
subjects between studies. The current study also differed from prior phase III trials of 
adjuvant radiation therapy in the use of an initial pelvic field and prescribed dose of 6660 
cGy as compared to 6000–6400 used in previous phase III trials including SWOG 8794, the 
comparator for the present series. The results of a DART 01/05 trial indicating benefit to 
extended ADT treatment in addition to dose escalated radiation in primary treatment of 
high-risk patients suggests the benefit seen in the current study is unlikely due to the use of 
pelvic radiation therapy and slightly higher doses as commonly used currently.15 Use of 
ADT may also provide a lead time bias in defining treatment failure due to time required for 
testosterone recovery. Ultimately, the contribution of docetaxel and ADT, and whether 
extended duration of ADT would provide further benefit are questions that only a phase III 
trial can definitively answer.
The optimal approach to management of high-risk patients remains an important question to 
be answered in the post-prostatectomy setting. NRG Oncology RTOG 0621 has revealed a 
very high risk subset of patients post-prostatectomy at near term risk of disease progression 
even with combined local and systemic therapy. The results of the current study strongly 
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support further investigation of integration of systemic therapies including both ADT and 
chemotherapy with post-operative radiation in this patient population.
Conclusions
Addition of docetaxel and ADT to ART for men at high-risk of failure despite both surgery 
and radiation therapy resulted in significant improvement in three-year freedom from 
progression as compared to historical controls treated with radiation alone. While past 
randomized trials have proven the efficacy of ART in selected subsets of men after radical 
prostatectomy, the individual contribution of hormonal therapy and docetaxel in this setting 
will require additional appropriately designed prospective randomized studies.
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Precis
Addition of docetaxel and ADT to ART for men at high-risk of failure despite both 
surgery and radiation therapy resulted in significant improvement in three-year freedom 
from progression as compared to historical controls treated with radiation alone.
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Figure 1. 
NRG Oncology RTOG 0621 CONSORT Flow Diagram
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Figure 2. 
Kaplan-Meier estimates of freedom from progression. Overall, the estimated three-year FFP 
rate is 73.0% (95%CI 62.9–83.1). Three-year FFP rates are 92.3% (95%CI 83.9–100) and 
51.4% (95%CI 34.9–68.0) for patients with post-RP nadir PSA ≤ 0.2 ng/ml and > 0.2, 
respectively. Censored observations are denoted by “/”.
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Table 1
Patient and tumor characteristics (n=74)
Age (years)
 Median 62
 Minimum – maximum 43 – 75
 First quartile – third quartile 55 – 66
 ≤ 65 52 70.3%
 > 65 22 29.7%
Race
 American Indian or Alaskan native 2 2.7%
 Black or African-American 6 8.1%
 White 65 87.8%
 Unknown 1 1.4%
Ethnicity
 Hispanic or Latino 1 1.4%
 Not Hispanic or Latino 66 89.2%
 Unknown 7 9.5%
Zubrod performance status
 0 69 93.2%
 1 5 6.8%
Prostatectomy margin
 Positive 43 58.1%
 Negative 31 41.9%
T stage, pathologic
 pT2a 1 1.4%
 pT2c 2 2.7%
 pT3 (not otherwise specified) 2 2.7%
 pT3a 28 37.8%
 pT3b 40 54.1%
 pT4 1 1.4%
PSA (postoperative nadir, ng/mL)
 ≤ 0.1 33 44.6%
 > 0.1 to 0.2 6 8.1%
 > 0.2 35 47.3%
PSA (study entry, ng/mL)
 ≤ 0.1 27 36.5%
 > 0.1 to 0.2 7 9.5%
 > 0.2 40 54.1%
Gleason score, combined
 7 13 17.6%
 8 19 25.7%
 9 41 55.4%
 10 1 1.4%
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Table 2
Three-year time-to-event estimates
Endpoint
Number of events
3-year estimate (%) 95% confidence interval (%)First 3 years Total
Freedom from progression 20 26 73.0 62.9 to 83.1
Local-regional progression 0 0 0.0 Not applicable
Distant metastasis 5 11 6.8 2.5 to 14.0
Biochemical failure 19 25 25.7 16.3 to 36.1
Overall survival 1 3 98.6 96.0 to 100
Prostate cancer death 0 2 0.0 Not applicable
Non-prostate-cancer death 1 1 1.4 0.1 to 6.5
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Table 3
Univariate and multivariate analysis of prognostic factors for freedom from progression and biochemical 
failure
Endpoint Variable Hazard ratio 95% CI p-value
Freedom from progression Univariate analysis
Gleason [1] 0.87 0.33 to 2.32 0.78
PSA [2] 13.45 4.00 to 45.22 <0.001
Multivariate analysis
Gleason [1] 3.14 1.16 to 8.50 0.02
PSA [2] 20.01 5.81 to 68.95 <0.001
Biochemical failure Univariate analysis
Gleason [1] 1.14 0.39 to 3.32 0.81
PSA [2] 12.26 3.64 to 41.27 <0.001
Multivariate analysis
Gleason [1] 4.13 1.39 to 12.28 0.01
PSA [2] 19.72 5.72 to 67.99 <0.001
CI: confidence interval.
[1]Gleason score, combined (8–10 vs. 7).
[2]
PSA (postoperative nadir, ng/mL) (> 0.2 vs. ≤ 0.2).
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Table 4
Selected Treatment-Related Acute Adverse Events (n=74)
CTCAE category Grade 2 Grade 3 Grade 4
CTCAE term n % n % n %
Maximum 15 20.3 23 31.1 34 45.9
Blood/bone marrow
 Hemoglobin decreased 12 16.2 0 0.0 0 0.0
 Leukopenia 2 2.7 26 35.1 10 13.5
 Lymphopenia 10 13.5 10 13.5 2 2.7
 Neutropenia 2 2.7 12 16.2 30 40.5
Infection
 Febrile neutropenia 0 0.0 2 2.7 1 1.4
 Urinary tract infection [with Grade 3–4 ANC] 0 0.0 1 1.4 0 0.0
Neurology
 Peripheral sensory neuropathy 10 13.5 1 1.4 0 0.0
Constitutional symptoms
 Fatigue 42 56.8 1 1.4 0 0.0
Gastrointestinal
 Constipation 8 10.8 1 1.4 0 0.0
 Diarrhea 14 18.9 2 2.7 0 0.0
 Ileus 0 0.0 1 1.4 0 0.0
 Nausea 7 9.5 0 0.0 0 0.0
 Vomiting 4 5.4 1 1.4 0 0.0
Renal/genitourinary
 Urinary frequency 15 20.3 1 1.4 0 0.0
 Urinary incontinence 15 20.3 0 0.0 1 1.4
CTCAE: Common Terminology Criteria for Adverse Events, version 3.0.
ANC: absolute neutrophil count.
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Table 5
Selected Treatment-Related Late Adverse Events (n=74)
CTCAE category Grade 2 Grade 3 Grade 4
CTCAE term n % n % n %
Maximum 36 48.6 6 8.1 2 2.7
Blood/bone marrow
 Lymphopenia 0 0.0 1 1.4 0 0.0
Infection
 Sepsis [with normal or Grade 1–2 ANC] 0 0.0 1 1.4 0 0.0
 Skin infection [with normal or Grade 1–2 ANC] 0 0.0 1 1.4 0 0.0
 Urinary tract infection [with unknown ANC] 1 1.4 0 0.0 0 0.0
Pain
 Pain [not otherwise specified] 0 0.0 1 1.4 0 0.0
Gastrointestinal
 Proctitis 2 2.7 0 0.0 0 0.0
Renal/genitourinary
 Cystitis 2 2.7 1 1.4 0 0.0
 Ureteric obstruction 0 0.0 2 2.7 0 0.0
 Urinary frequency 6 8.1 0 0.0 0 0.0
 Urinary incontinence 16 21.6 0 0.0 2 2.7
CTCAE: Common Terminology Criteria for Adverse Events, version 3.0.
ANC: absolute neutrophil count.
Cancer. Author manuscript; available in PMC 2018 July 01.
